ONC stock news · BeOne Medicines
Get alerts for ONC
Follow BeOne Medicines (ONC) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ONCFree on the App Store and Google Play, or on the web.
Citizens analyst Reni J. Benjamin kept a positive rating on BeOne Medicines and raised the price target to $463.
Good for ONCBeOne Medicines' analyst target rose from $405 to $463, and the analyst kept an Outperform rating. This favors BeOne's outlook, but reflects an analyst's view, not new company results.
Nine additional pharmaceutical partnerships announced by Trump increase total agreements to 26 — RFK Jr. shares insights on 'deeply emotional' discussions with the President.
Bad for ONCBeOne Medicines is named among companies required to offer outpatient discounts, exposing it to lower U.S. pricing and revenue headwinds.